Fixed-Duration CALQUENCE Plus Venetoclax, With or Without Obinutuzumab, Significantly Improved Progression-Free Survival in 1st-Line Chronic Lymphocytic Leukemia in AMPLIFY Phase III Trial
July 30, 2024
July 30, 2024
WILMINGTON, Delaware, July 30 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Favorable trend in overall survival was also observed
* * *
Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca's CALQUENCE(R) (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, demonstrated a statistically significant and clinically . . .
* * *
Favorable trend in overall survival was also observed
* * *
Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca's CALQUENCE(R) (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, demonstrated a statistically significant and clinically . . .